Orgenesis licenses cancer vaccine from Columbia

Orgenesis gained an exclusive license to a cellular vaccination product platform from Columbia University. Orgenesis Inc. (OTCQX:ORGS) will fund research at the university to develop the technology to treat pancreatic, hepatic and cholangiocarcinoma cancers.

The platform uses whole cancer cells as a source of antigens and a patient’s dendritic cells and macrophages to present the cancer antigens to the immune system. Orgenesis said the dual-vaccine design is meant to minimize a cancer cell's ability to mutate and evade immune system response...